EU/U.S. MRA cannot include public access to inspection reports, EC administrator contends.
GMP INSPECTIONS REPORT PUBLIC ACCESS UNDER MRA OPPOSED BY EU, European Commission Administrator Gudrun Gallhoff told the University of Texas International Industrial Pharmacy Conference Feb. 26 in Austin, Tex. "We have agreed to deliver those reports, taking the burden on us of translating those reports as necessary and giving them to the U.S. government," Gallhoff stated. "What we cannot agree to is that those reports go public, because it's against the law of several member states." FDA's lead negotiator on the MRA, International Affairs Director Walter Batts, acknowledged that public availability of information in inspection reports "remains an issue."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth